Johnson & Johnson has confirmed its plans to acquire Firefly Bio for $1 billion, marking a strategic investment in the burgeoning field of KRAS inhibitors.
This acquisition is seen as a way for J&J to strengthen its oncology pipeline, which is increasingly focused on innovative cancer treatment options.
The KRAS inhibitors market has gained attention recently, making this a timely move for the pharmaceutical giant as it seeks to expand its capabilities in cancer therapies.